BioGaia Description

BioGaia Probiotic chewable tab: Small size tablet (10.3 mm) cream coloured convex shaped with faint brownish spot, chewable mottled tablet.
Active ingredient: Each 450 mg tablet contains Lactobacillus reuteri DSM 17938 7.65 mg. One tablet contains a minimum of 100 million CFU live L. reuteri.
BioGaia Probiotic Chewable Tablets contain Lactobacillus reuteri which naturally occurs in the human body that helps in the maintenance of good health. L. reuteri DSM 17938 was originally isolated from human milk and has been shown to survive passage through the gastrointestinal tract and to adhere to the intestinal mucosa.
Several studies have shown significant clinical effects of L. reuteri DSM 17938 in functional gastrointestinal disorders such as functional constipation and functional abdominal pain. Four randomized, double-blind, placebo-controlled studies showed that L. reuteri DSM 17938 significantly reduced constipation symptoms and quality of life in children and adults with functional constipation. Studies have also shown that L. reuteri DSM 17938 increases days without pain and reduces severity pain in children with functional abdominal pain.
In addition, studies have shown that L. reuteri DSM 17938 protects against infections and may also reduce gastrointestinal antibiotic-associated side-effects.
L. reuteri DSM 17938 has been tested in more than 170 clinical studies and proven effective and safe for children and adults.
Excipients/Inactive Ingredients: Isomalt, xylitol, sucrose esters of fatty acid, hydrogenated palm oil, lemon-lime flavouring and citric acid (anhydrous).
BioGaia Probiotic oral drops: White yellow opaque suspension.
Active ingredient: One dose/5 drops (0.185 ml) contains 0.10 g or a minimum of 100 million CFU live Lactobacillus reuteri DSM 17938.
BioGaia Probiotic Drops is a health supplement containing Lactobacillus reuteri which naturally occurs in the human body that helps in the maintenance of good health. L. reuteri DSM 17938 was originally isolated from human milk and has been shown to survive passage through the gastrointestinal tract and to adhere to the intestinal mucosa.
Numerous studies have shown significant clinical effects of L. reuteri DSM 17938 in functional gastrointestinal disorders such as colic, regurgitation, functional constipation, and functional abdominal pain. Seven randomized, double-blind, placebo-controlled studies showed that L. reuteri DSM 17938 significantly reduced crying time in infants with colic. Studies have also shown that L. reuteri DSM 17938 increases bowel movements in infants with functional constipation and decreases regurgitation episodes in infants with gastroesophageal reflux. A preventative effect against gastrointestinal disorders has also been shown in healthy newborns.
In addition, studies have shown that L. reuteri DSM 17938 helps recover from acute gastroenteritis and protects against infections. Six randomized, controlled studies showed that L. reuteri DSM 17938 significantly reduced duration and severity of diarrhoea, as well as vomiting in infants and children with acute gastroenteritis. Also, L. reuteri DSM 17938 has been shown to reduce the number of infections and antibiotic use and to reduce absence from day care. Clinical data suggest that L. reuteri DSM 17938 may also reduce gastrointestinal antibiotic-associated side-effects.
L. reuteri DSM 17938 has been tested in more than 170 clinical trials and proven both effective and safe for children.
Excipients/Inactive Ingredients: Sunflower oil, caprylic triglyceride, silicon dioxide.
BioGaia Prodentis loz: White round shape lozenge with blue and beige spots, with mint smell and taste. Having a diameter of 13 mm and thickness of 4.9-5.3 mm.
Active ingredients: Each 800 mg lozenge contains Lactobacillus reuteri DSM 17938 18.1 mg and Lactobacillus reuteri ATCC PTA 5289 18.1 mg. One lozenge contains a minimum of 200 million live CFU L. reuteri.
BioGaia Prodentis Lozenges is a health supplement containing lactic acid bacterium (Lactobacillus reuteri DSM 17938 and Lactobacillus reuteri ATCC PTA 5289). The probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 are human isolates. L. reuteri DSM 17938 was originally isolated from human milk, and L. reuteri ATCC PTA 5289 from the oral cavity. Both strains form biofilm and adhere to oral surfaces and have been shown to colonize the oral cavity after ingestion.
Numerous studies have shown significant clinical effects of L. reuteri Prodentis for oral health conditions, such as gingivitis, periodontitis, and caries-related risk factors. Two randomized, double-blind, placebo-controlled studies showed that L. reuteri Prodentis significantly reduced bleeding on probing and gingival index in healthy individuals with gingivitis or pregnancy gingivitis. In addition, four randomized, double-blind, placebo-controlled studies showed that L. reuteri Prodentis reduced probing pocket depth and increased clinical attachment level, when used as an adjuvant to scaling and root planning in patients with periodontitis. L. reuteri Prodentis has also been shown to reduce caries-associated bacteria, i.e. Streptococcus mutans.
L. reuteri Prodentis has been tested in more than 60 clinical trials and proven to be safe for children and adults.
Excipients/Inactive Ingredients: Isomalt, hydrogenated palm oil, sucrose ester of fatty acids, peppermint flavour, menthol, peppermint oil, sucralose.
BioGaia Protectis oral powd: White to off-white powder, odorless.
Each 0.36 g sachet contains: Limosilactobacillus reuteri* DSM 17938 0.0054 g. (One dose contains a minimum of 100 million CFU live L. reuteri).
BioGaia Protectis Powder is a health supplement containing Lactobacillus reuteri which naturally occurs in the human body that helps in the maintenance of good health. L. reuteri DSM 17938 was originally isolated from human milk and has been shown to survive passage through the gastrointestinal tract and to adhere to the intestinal mucosa.
Numerous studies have shown significant clinical effects of L. reuteri DSM 17938 in functional gastrointestinal disorders such as colic, regurgitation, functional constipation, and functional abdominal pain. Seven randomized, double-blind, placebo-controlled studies showed that L. reuteri DSM 17938 significantly reduced crying time in infants with colic. Studies have also shown that L. reuteri DSM 17938 increases bowel movements in infants with functional constipation and decreases regurgitation episodes in infants with gastroesophageal reflux. A preventative effect against gastrointestinal disorders has also been shown in healthy newborns.
In addition, studies have shown that L. reuteri DSM 17938 helps recover from acute gastroenteritis and protects against infections. Six randomized, controlled studies showed that L. reuteri DSM 17938 significantly reduced duration and severity of diarrhoea, as well as vomiting in infants and children with acute gastroenteritis. Also, L. reuteri DSM 17938 has been shown to reduce the number of infections and antibiotic use and to reduce absence from day care. Clinical data suggest that L. reuteri DSM 17938 may also reduce gastrointestinal antibiotic-associated side-effects.
L. reuteri DSM 17938 has been tested in more than 170 clinical trials and proven to be safe for infants and children.
*Previously known as Lactobacillus reuteri
Excipients/Inactive Ingredients: Maltodextrin.
BioGaia Protectis Probiotic with Vitamin D3 oral drops: Colorless to yellow opaque suspension with characteristic smell and taste.
Each 0.035 ml drop contains: Limosilactobacillus reuteri* DSM 17938 0.7 mg Vitamin D3 80 IU. (One dose contains a minimum of 100 million CFU live L. reuteri and 400 IU of vitamin D3).
BioGaia Protectis Probiotic with Vitamin D3 Drops is a health supplement containing Limosilactobacillus reuteri* DSM 17938 and vitamin D3 that helps in the maintenance of good health. L. reuteri DSM 17938 was originally isolated from human milk and has been shown to survive passage through the gastrointestinal tract and to adhere to the intestinal mucosa.
Numerous studies have shown significant clinical effects of L. reuteri DSM 17938 in functional gastrointestinal disorders such as colic, regurgitation, functional constipation, and functional abdominal pain. Seven randomized, double-blind, placebo-controlled studies showed that L. reuteri DSM 17938 significantly reduced crying time in infants with colic. Studies have also shown that L. reuteri DSM 17938 increases bowel movements in infants with functional constipation and decreases regurgitation episodes in infants with gastroesophageal reflux. A preventative effect against gastrointestinal disorders has also been shown in healthy newborns.
In addition, studies have shown that L. reuteri DSM 17938 helps recover from acute gastroenteritis and protects against infections. Six randomized, controlled studies showed that L. reuteri DSM 17938 significantly reduced duration and severity of diarrhoea, as well as vomiting in infants and children with acute gastroenteritis. Also, L. reuteri DSM 17938 has been shown to reduce the number of infections and antibiotic use and to reduce absence from day care. Clinical data suggest that L. reuteri DSM 17938 may also reduce gastrointestinal antibiotic-associated side-effects.
Vitamin D contributes to the normal function of the immune system in children and is also needed for normal growth and development of bone in children.
*Previously known as Lactobacillus reuteri
Excipients/Inactive Ingredients: Sunflower oil, medium chain triglycerides oil, silicon dioxide.